Contract facts
FederalNo full NAICS 541990 intel page yet. Browse NAICS intelligence
S4 TO 108 NCATS GENE THERAPY VECTOR is a federal award for National Institutes Of Health Olao held by Medical Science & Computing, LLC. Estimated value $9M ($6.3M obligated). Current period of performance ends Sep 29, 2026. Place of performance: ROCKVILLE MD.
Recompete timing
PublicCurrent PoP ends Sep 29, 2026 (40 days remaining). Agencies typically plan 12–18 months ahead — at 1.3 months out, that window is already open. The buying decision is likely already in motion.
Incumbent footprint
Public recordMedical Science & Computing, LLC — $89.1M obligated across 575 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 75N98021F00357?
75N98021F00357 (S4 to 108 NCATS GENE therapy VECTOR) is a National Institutes Of Health Olao award with a potential value of $9M, currently held by Medical Science & Computing, LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded 75N98021F00357?
National Institutes Of Health Olao awarded 75N98021F00357 to Medical Science & Computing, LLC (potential $9M).
Who is the incumbent on 75N98021F00357?
Medical Science & Computing, LLC is the incumbent with $89.1M across 575 related awards in SCOUT’s public footprint. The current period of performance ends Sep 29, 2026.
When does Medical Science & Computing, LLC’s 75N98021F00357 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 29, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.